Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Development of EQ-6, a Novel Analogue of Ethoxyquin to Prevent Chemotherapy-Induced Peripheral Neuropathy

Neurotherapeutics(2021)10.1007/s13311-021-01093-8Source: DataRank Database

Development of EQ-6, a Novel Analogue of Ethoxyquin to Prevent Chemotherapy-Induced Peripheral Neuropathy is a research paper published in Neurotherapeutics (2021). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.57)OA: bronzeTopics (49)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Jing Zhu ORCID,Xinghua Luan ORCID,Jun-Soon Kim,Byoungchol Oh,Cory Brayton ORCID

Live enrichment

PubMed:34291431 PMC:PMC8608988 OpenAlex:https://openalex.org/W3186766964

National Institute of Neurological Disorders and Stroke

Grant: NS091260

Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

Grant: 119309

NINDS NIH HHS

Grant: R01 NS091260

National Institutes of Health

Grant: 5R01NS091260-03

Mechanism of neuroprotection in chemotherapy induced peripheral neuropathy

FWCI

0.57

Citation Percentile

0.7%

Citation Trend

2022

2023

2024

bronzeLicense: Elsevier Non-Commercial

journalhttps://link.springer.com/content/pdf/10.1007/s13311-021-01093-8.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s13311-021-01093-8.pdf

publisherhttps://link.springer.com/article/10.1007/s13311-021-01093-8/fulltext.html

publisherhttps://api.elsevier.com/content/article/PII:S1878747923007894?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1878747923007894?httpAccept=text/plain

Fields of Study

Cancer Treatment and PharmacologyToxin Mechanisms and ImmunotoxinsPain Mechanisms and Treatments0301 basic medicine03 medical and health sciences0302 clinical medicineAnimalsAntineoplastic AgentsCells, CulturedDrug DevelopmentEthoxyquinFemaleHumansMaleMicePeripheral Nervous System DiseasesRatsRats, Sprague-Dawley

MeSH Terms

Drug DevelopmentAnimalsAntineoplastic AgentsCells, CulturedEthoxyquinFemaleHumansMalePeripheral Nervous System DiseasesRats, Sprague-DawleyMiceRats

Keywords

PharmacologyNeuroprotectionMedicineEthoxyquinChemistryBiochemistryAntioxidantChemotherapy-induced Peripheral NeuropathyMalePeripheral Nervous System DiseasesAntineoplastic AgentsRatsRats, Sprague-DawleyMiceDrug DevelopmentAnimalsHumansFemaleCells, Cultured

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being